Emerging targets in human lymphoma: targeting the MYD88 mutation
James Q Wang,* Yogesh S Jeelall,* Keisuke Horikawa* Department of Immunology, The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia *All authors contributed equally to this manuscript Abstract: B cell neoplasms co-opt the molecular machinery of normal B...
Main Authors: | Wang JQ, Jeelall YS, Horikawa K |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-08-01
|
Series: | Blood and Lymphatic Cancer: Targets and Therapy |
Online Access: | http://www.dovepress.com/emerging-targets-in-human-lymphoma-targeting-the-myd88-mutation-a14017 |
Similar Items
-
Toll-like receptors and cancer: MYD88 mutation and inflammation
by: James Q Wang, et al.
Published: (2014-07-01) -
Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent Inflammation
by: Wu Luo, et al.
Published: (2022-11-01) -
From monogenic lupus to TLR7/MyD88-targeted therapy
by: Min Wang, et al.
Published: (2022-09-01) -
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
by: Annika Nelde, et al.
Published: (2017-03-01) -
MYD88 and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy
by: Rongrong Chen, et al.
Published: (2022-01-01)